Ganglioside‐exposed dendritic cells inhibit T‐cell effector function by promoting regulatory cell activity

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Immunology

• Publication date

  2011-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2567.2010.03348.xPMID 20875076PMCID PMC3015083
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Shedding of GD2 ganglioside in patients with retinoblastoma

  2009cited by this paper
• Tuning microenvironments: induction of regulatory T cells by dendritic cells.

  2008cited by this paper
• Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function.

  2008cited by this paper
• Inhibition of TLR Activation and Up-Regulation of IL-1R-Associated Kinase-M Expression by Exogenous Gangliosides1

  2008cited by this paper
• GM1 and tumor necrosis factor-alpha, overexpressed in renal cell carcinoma, synergize to induce T-cell apoptosis.

  2008cited by this paper
• MUC1 mucin is a negative regulator of toll-like receptor signaling.

  2008cited by this paper
• Immunosuppressive strategies that are mediated by tumor cells.

  2007cited by this paper
• Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance.

  2007cited by this paper
• Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth.

  2007cited by this paper
• Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling.

  2006cited by this paper
• GM2 expression in renal cell carcinoma: potential role in tumor-induced T-cell dysfunction.

  2006cited by this paper
• Expression of the putatively regulatory T-cell marker FOXP3 by CD4(+)CD25+ T cells after pediatric hematopoietic stem cell transplantation.

  2006cited by this paper
• The immunoregulatory effects of gangliosides involve immune deviation favoring type‐2 T cell responses

  2006cited by this paper
• Modulation of CD4 Th Cell Differentiation by Ganglioside GD1a In Vitro1

  2005cited by this paper
• IRAK-M is a negative regulator of Toll-like receptor signaling.

  2002cited by this paper
• Ganglioside GD1a impedes lipopolysaccharide-induced maturation of human dendritic cells.

  2002cited by this paper
• Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function.

  2001cited by this paper
• Enhancement of Epidermal Growth Factor Signaling and Activation of Src Kinase by Gangliosides*

  2001cited by this paper
• Tumor gangliosides inhibit the tumor-specific immune response.

  1999cited by this paper
• Regulation of naive T cell differentiation by varying the potency of TCR signal transduction.

  1999cited by this paper
• Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.

  1999cited by this paper
• CD4 regulation of TCR signaling and T cell differentiation following stimulation with peptides of different affinities for the TCR.

  1998cited by this paper
• Inhibition of LPS-mediated cell activation in vitro and in vivo by gangliosides.

  1994cited by this paper
• Gangliosides inhibit T-lymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors.

  1993cited by this paper
• Shed tumor gangliosides and progression of human neuroblastoma.

  1990cited by this paper
• Selective development of CD4+ T cells in transgenic mice expressing a class II MHC-restricted antigen receptor

  1989cited by this paper
• Ganglioside GD3 shedding by human malignant melanoma cells

  1989cited by this paper
• The suppressive effect of gangliosides upon IL 2-dependent proliferation as a function of inhibition of IL 2-receptor association.

  1986cited by this paper
• Detection of a tumour-associated ganglioside in plasma of patients with neuroblastoma.

  1985cited by this paper
• Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro.

  1984cited by this paper
• Shedding and immunoregulatory activity of YAC-1 lymphoma cell gangliosides.

  1983cited by this paper
• Letter: Recycling disposables.

  1974cited by this paper

• Targeting GD2 with naxitamab overcomes GD3 synthase-driven immune suppression in triple-negative breast cancer

  2025cites this paper
• Prospects of anti-GD2 immunotherapy for retinoblastoma

  2024cites this paper
• Bioactive sphingolipids as emerging targets for signal transduction in cancer development.

  2024cites this paper
• GD2-targeting therapy: a comparative analysis of approaches and promising directions

  2024cites this paper
• Limited impact of cancer-derived gangliosides on anti-tumor immunity in colorectal cancer

  2024influential citation
• The biological role and immunotherapy of gangliosides and GD3 synthase in cancers

  2023cites this paper
• Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment

  2023cites this paper
• Multiplicity of Glycosphingolipid-Enriched Microdomain-Driven Immune Signaling

  2021cites this paper
• Sialic acids: An Avenue to Target Cancer Progression, Metastasis, and Resistance to Therapy

  2021cites this paper
• Metabolic programming in dendritic cells tailors immune responses and homeostasis

  2021cites this paper
• Upregulation of CD3ζ and L‐selectin in antigen‐specific cytotoxic T lymphocytes by eliminating myeloid‐derived suppressor cells with doxorubicin to improve killing efficacy of neuroblastoma cells in vitro

  2021cites this paper
• Targets and Antibody Formats for Immunotherapy of Neuroblastoma

  2020cites this paper
• Sialic Acids and TAGs of Tumor Cells to Escape Immune Surveillance and Immune Editing

  2020cites this paper
• Ganglioside Biochemistry

  2020cites this paper
• Glycosylation and Antitumor Immunity.

  2019cites this paper
• Sialic acid mimetics for cancer immunotherapy

  2017cites this paper
• The Sweet Side of Immune Evasion: Role of Glycans in the Mechanisms of Cancer Progression

  2016cites this paper
• Ganglioside GM2 mediates migration of tumor cells by interacting with integrin and modulating the downstream signaling pathway.

  2016cites this paper
• Disialoganglioside GD2 as a therapeutic target for human diseases

  2015cites this paper
• Antitumor and cytotoxic properties of a humanized antibody specific for the GM3(Neu5Gc) ganglioside.

  2015cites this paper
• Glycolipid Sensing and Innate Immunity in Paracoccidioidomycosis

  2014cites this paper
• Sweet escape: sialic acids in tumor immune evasion.

  2014cites this paper
• Glycobiology of Neuroblastoma: Impact on Tumor Behavior, Prognosis, and Therapeutic Strategies

  2014cites this paper
• Gangliosides, immunity, infection and inflammation.

  2013cites this paper
• Tumor gangliosides and T cells: a deadly encounter.

  2012influential citation
• Efeito de glicolipídios de Paracoccidioides brasiliensis sobre a resposta imune inata e adaptativa de indivíduos saudáveis curados de paracoccidioidomicose.

  2012cites this paper
• Meeting report: regulatory myeloid cells.

  2011cites this paper
• Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

  2011cites this paper
• Modulation des cellules dendritiques et macrophages : implications dans le cancer et l'athérosclérose

  2010cites this paper